References
1. Alon T., Hemo I., Itin A. et al. Vascular endothelial growth factor acts as survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity // Nat. Med. - 1995. - Vol. 1. - P. 1024-1028.
2. Aoki M., Morishita R., Taniyama Y. et al. Angiogenesis induced by hepatocyte growth factor in noninfarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets // Gene Ther. - 2000. - Vol. 7. - P. 417-427.
3. Autiero M., Waltenberger J., Communi D. et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 // Nat. Med. - 2003. - Vol. 9. - P. 936-943.
4. Baffour R., Berman J., Garb J. L. et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor // J. Vasc. Surg. - 1992. - Vol. 16. - P. 181-191.
5. Baffour R., Garb J. L., Kaufman J. et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model // J. Surg. Res. - 2000. - Vol. 93. - P. 219-229.
6. Banai S., Jaklitsch M. T., Casscells W. et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium // Circ. Res. - 1991. - Vol. 69. - P. 76-85.
7. Battler A., Scheinowitz M., Bor A. et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium // J. Amer. Coll. Cardiol. - 1993. - Vol. 22. - P. 2001-2006.
8. Cao G., O,Brien C., Zhou Z. et al. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration // Amer. J. Physiol. Heart Circ. Physiol. - 2002. - Vol. 282. - P. C1181-1190.
9. Cao R., Brakenhielm E., Pawliuk R. et al. Angiogenic synergism, vascular stability and improvement of hindlimb ischemia by a combination of PDGF-BB and FGF-2 // Nat. Med. - 2003. - Vol. 9. - P. 604-613.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis // Ibid. - 2000. - Vol. 6. - P. 389-395.
11. Carmeliet P., Moons L., Luttun A. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions // Ibid. - 2001. - Vol. 7. - P. 575-583.
12. Carmeliet P., Ferreira V., Breie G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele // Nature. - 1996. - Vol. 380. - P. 435-439.
13. Cuevas P., Carceller F., Lozano R. M. et al. Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion // Growth Factor. - 1997. - Vol. 2. - P. 15-40.
14. Cuevas P., Reimers D., Carceller F. et al. Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury // Eur. J. Med. Res. - 1997. - Vol. 2. - P. 465-468.
15. Darland D., D,Amore P. Blood vessel maturation: vascular development comes of age // J. Clin. Invest. - 1999. - Vol. 103. - P. 157-158.
16. De Muinck E., Simons M. Re-evaluating neovascularization // J. Mol. Cell. Cardiol. - 2004. - Vol. 36. - P. 25-32.
17. Deroanne C. F., Hajitou A., Calberg-Bacq C. M. et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression // Cancer. Res. - 1997. - Vol. 57. - P. 5590-5597.
18. Devlin G. P., Fort S., Yu E. et al. Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model // Can. J. Cardiol. - 1999. - Vol. 15. - P. 676-682.
19. Diendl E., Hoefer I., Fernandez B. et al. Involvement of the fibroblast growth factor systev in adaptive and chemokine-induced arteriogenesis // Circ. Res. - 2003. - Vol. 92. - P. 561-568.
20. Dor Y., Djonov V., Abramovitch R. et al. Conditional switching of VEGF provides new insights into adult neovascularizadon and pro-angiogenic therapy // EMBO J. - 2002. - Vol. 21. - P. 1939-1947.
21. Elicieri B. Integrin and growth factor receptor crosstalk // Circ. Res. - 2001. - Vol. 89. - P. 1104-1110.
22. Ferrara N., Alitano K. Clinical applications of angiogenic growth factors and their inhibitors // Nat. Med. - 1999. - Vol. 5. - P. 1359-1364.
23. FGF-4 gene therapy GENERX-Collateral Therapeutics // BioDrugs. - 2002. - Vol. 16. - P. 75-76.
24. Folkman J. Tumor angiogenesis: therapeutic implications // New Engl. J. Med. - 1971. - Vol. 285. - P. 1182-1186.
25. Frenkel-Denkberg G., Gershon D., Levy A. The function of hypoxia-inducible factor 1 (HIF-1) is impraired in senescent mice // FEBS Lett. - 1999. - Vol. 462. - P. 341-344.
26. Gao Y., Lecker S., Post M. J. et al. Inhibition of ubiquitin- proteasome pathway-ediated I kappa B alpha degradation by a naturaly occurring antibacterial peptide // J. Clin. Invest. - 2000. - Vol. 106. - P. 439-448.
27. Giordano F. J., Ping P., McKirnan M. D. et al. Intracoronary gene transfer of fibroblast growth factor- 5 increases blood flow and contractile function in an ischemic region of the heart // Nat. Med. - 1996. - Vol. 2. - P. 534-539.
28. Gospodarowicz D., Cheng J., Lui G. M. et al. Corpus luteum angiogenic factor is related to fibroblast growth factor // Endocrinology. - 1985. - Vol. 117.- P. 2383-2391.
29. Grines C. L., Watkins M. W., Helmer G. et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris // Circulation. - 2002. - Vol. 105. - P. 1291-1297.
30. Harada K., Grossman W., Friedman M. et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts // J. Clin. Invest. - 1994. - Vol. 94. - P. 623-630.
31. Hata Y., Rook S. L., Aiello L. P. Basic fibroblast growth factory induces expression of VEGF receptor KDR through a proteinkinase C and p44/p42 mitogen-activated proteinkinase-dependent pathway // Diabetes. - 1999. - Vol. 48. - P. 1145-1155.
32. Hattori K., Heissig B., Wu Y. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment // Nat. Med. - 2002. - Vol. 8. - P. 841-849.
33. Helmlinger G., Endo M., Ferrara N. et al. Formation of endothelial cell networks // Nature. - 2000. - Vol. 405. - P. 139-141.
34. Henry T., Annex B., Azrin M. et al. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis // Circulation. - 2003. - Vol. 107. - P. 1359-1365.
35. Hood J., Bednarski M., Frausto R. et al. Tumor regression by targeted gene delivery to the neovasculature // Science. - 2002. - Vol. 296. - P. 2404-2407.
36. Horowitz A., Simons M. Regulation of syndecan-4 phosphorylation in vivo // J. Biol. Chem. - 1998. - Vol. 273. - P. 109l4-10918.
37. Horowitz A., Tkachenko E., Simons M. et al. Fibroblast growth factor-specific modulation of cellular response by syndecan-4 // J. Cell. Biol. - 2002. - Vol. 157. - P. 715-725.
38. Huang Z., Chen K., Huang P. L. et al. bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice // Amer. J. Physiol. - 1997. - Vol. 272. - P. Hl401-1405.
39. Jackson D. The unfolding tale of PECAM-1 // FEBS Lett. - 2003. - Vol. 540. - P. 7-14.
40. Jiang Z. S., Padua R. R., Ju H. et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C // Amer. J. Physiol. Heart Circ. Physiol. - 2002. - Vol. 282. - P. H1071-1080.
41. Kasahara H., Tanaka E., Fukuyama N. et al. Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast growth factor 4 plasmid in rabbit hindlimb ischemia // J. Amer. Coll. Cardiol. - 2003. - Vol. 4l. - P. 1056-1062.
42. Khurana R., Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease // Trends Cardiovasc. Med. - 2003. - Vol. 13. - P. 116-122.
43. Kojima T., Takagi A., Maeda M. et al. Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction // Thromb. Haemost. - 2001. - Vol. 85. - P. 793-799.
44. Kola I., Brookes S., Green A. et al. The Ets1 transcription factor is widely expressed during murine embryo development and is associated cwith mesodermal cells involved in morphogenetic processes such as organ formation // Proc. Natl. Acad. Sci. USA. - 1993. - Vol. 90. - P. 7588-7592.
45. Laham R. J., Sellke F. W., Edelman E. R. et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial // Circulation. - 1999. - Vol. 100. - P. 1865-1871
46. Laham R. J., Rezaee M., Post M. et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia // J. Pharmacol. Exp. Ther. - 2000. - Vol. 292. - P. 795-802.
47. Lazarous D. F., Scheinowitz M., Shou M. et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart // Circulation. - 1995. - Vol. 91. - P. l45-153.
48. Lee L. Y., Patel S. R., Hackett N. R. et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121 // Ann. Thorac. Surg. - 2000. - Vol. 69. - P. 14-23; discus. 23-24.
49. Lee S., Wolf P., Escudero R. et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction // N. Engl. J. Med. - 2000. - Vol. 342. - P. 626-633.
50. Li L., Couse T., Deleon H. et al. Regulation of syndecan- 4 expression with mechanical stress during the development of angioplasty-induced intimal thickening // J. Vasc. Surg. - 2002. - Vol. 36. - P. 361-370.
51. Li L., Post M., Volk R. et al. PR39, a peptide regulator of angiogenesis // Nat. Med. - 2000. - Vol. 6. - P. 49-55.
52. Li J., Partovian C., Hampton T. et al. Modulation of microvascular signaling by heparin sulfate matrix: studies in syndecan-4 transgenic mice // Microvasc. Res. - 2002. - Vol. 64. - P. 38-46.
53. Lopez J. J., Edelman E. R., Stamler A. et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia // Amer. J. Physiol. - 1998. - Vol. 274. - P. H930-966.
54. Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 // Nat. Med. - 2002. - Vol. 8. - P. 831-840.
55. Masseri A., Aranjo L., Finocchiaro M. Collateral circulation: heart, brain, kidney // Collateral development and function in man / Eds W. Schaper, J. Schaper. - Boston, VA: Kluwer Academic Publ., 1993. - P. 381-402.
56. Montesano R., Vassalli J. D., Baird A. et al. Basic fibroblast growth factor induces angiogenesis in vitro // Proc. Natl. Acad. Sci. USA. - 1986. - Vol. 83. - P. 7297-7301.
57. Murakami M., Horowitz A., Tang S. et al. Proteinkinase C (PKC) delta regulates PKC alpha activity in a Syndecan-4-dependent manner // J. Biol. Chem. - 2002. - Vol. 277. - P. 20367-20371.
58. Ortega S., Schaeffer M. T., Soderman D. et al. Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor // Ibid. - 1991. - Vol. 266. - P. 5842-5846.
59. Piali L., Hammel P. et al. СD31/ PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium // J. Cell. Biol. - 1995. - Vol. 130. - P. 451-460.
60. Post M., Bao J., Sato K. et al. Adenoviral PR-39 improves perfusion and function in a pig model of chronic myocardial ischemia // Circulation. - 2002. - Vol. 106. - P. II-275.
61. Post M., Simons M. The rational phase of therapeutic angiogenesis // Minerva Cardioangiol. - 2003. - Vol. 51. - P. 421-432.
62. Prechal J. T. Delivery on demand - a new era of gene therapy? // N. Engl. J. Med. - 2003. - Vol. 348. - P. 1282-1283.
63. Rajanayagam M. A., Shou M., Thirumurti V. et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs // J. Amer. Coll. Cardiol. - 2000. - Vol. 35. - P. 519-526.
64. Risau W., Flamme I. Vasculogenesis // Annu. Rev. Cell. Dev. Biol. - 1995. - Vol. 11. - P. 73-91.
65. Rissanen T. T., Markkanen J. E., Arve K. et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model // Faseb. J. - 2003. - Vol. 17. - P. 100-102.
66. Roethy W., Fiehn E., Suehiro K. et al. A growth factor mixture that significantly enhances angiogenesis in vivo // J. Pharmacol. Exp. Ther. - 2001. - Vol. 299. - P. 494-500.
67. Rohan R., Fernandez M. A., Udagawa T. et al. Genetic heterogeneity of angiogenesis in mice // FASEB J. - 2000. - Vol. 14. - P. 871-876.
68. Rosengart T. K., Budenbender K. T., Duenas M. et al. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin // J. Vasc. Surg. - 1997. - Vol. 26. - P. 302-312.
69. Sato K., Laham R. J., Perlman J. D. et al. Efficacy of intracoronary intravenous FGF-2 in a pig model of chronic myocardial ischemia // Ann. Thorac. Surg. - 2000. - Vol. 70. - P. 2113-2118.
70. Sato K., Wu T., Laham R. J. et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia // J. Amer. Coll. Cardiol. - 2001. - Vol. 37. - P. 6l6-623.
71. Schlaudraff K., Schumacher B., von Specht B. U. et al. Growth of «new» coronary vascular structures by angiogenetic growth factors // Eur. J. Cardiothorac. Surg. - 1993. - Vol. 7. - P. 637-643; discus. 643-644.
72. Schmeisser A., Graffy C., Daniel W. et al. Phenotipic overlap between monocytes and vascular endothelial cells // Adv. Exp. Med. Biol. - 2003. - Vol. 522. - P. 59-74.
73. Scholz D., Ziegelhoeffer T., Helisch A. et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice // J. Mol. Cell. Cardiol. - 2002. - Vol. 34. - P. 775-787.
74. Schultz A., Lavie L., Hochberg I. et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation // Circulation. - 1999. - Vol. 100. - P. 547-552.
75. Sellke F. W., Ruel M. Vascular growth factors and angiogenesis in cardiac surgery // Ann. Thorac. Surg. - 2003. - Vol. 75. - P. S685-690.
76. Semenza G. L. Signal transduction to hypoxia-inducible factor 1 // Biochem. Pharmacol. - 2002. - Vol. 64. - P. 993-998.
77. Shyu K. G., Chang H., Isner J. M. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia // Life Sci. - 2003. - Vol. 73. - P. 563-579.
78. Simons M., Laham R. J., Post M. J., Selike F. W. Therapeutic angiogenesis: Potential role of basic FGP in patients with severe ischemic heart disease // Bio. Drugs. - 2000. - Vol. 14. - P. 13-20.
79. Simons M. Therapeutic coronary angiogenesis: A fronte praecipitium a tergo lupi? // Amer. J. Physiol.- 2001. - Vol. 280. - P. H1923-H1927.
80. Simons M., Annex B. H., Laham R. J. et al. Pharmacological treatment of coronar artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial // Circulation. - 2002. - Vol. 105. - P. 788-793.
81. Simons M., Post M. Angiogenesis // Textbook of interventional cardiology / Ed. E. J. Topol. - Philadelphia: Saunders, 2003. - P. 757-759.
82. Solowiej A., Biswas P., Graesser D. et al. Lack of platelet endothelial cell adhesion molecule-1 attenuates foreign body inflammation because of decreased angiogenesis // Amer. J. Pathol. - 2003. - Vol. 162. - P. 953-962.
83. Springer M., Chen A., Kraft P. et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults // Moll. Cell. - 1998. - Vol. 2. - P. 549-558.
84. Stavri G. T., Zachary I. C., Baskerville P. A. et al. Basic fibroblast growth factor upreg-ulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia // Circulation. - 1995. - Vol. 92. - P. 11-14.
85. Sullivan G., Sarembock I., Linden J. The role of inflammation in vascular diseases // J. Leukoc. Biol. - 2000. - Vol. 67. - P. 591-602.
86. Tabata H., Silver M., Isner J. M. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo, critical role of secretion signal in use of naked DNA // Cardiovasc. Res. - 1997. - Vol. 35. - P. 470-479 // Erratum Cardiovasc. Res. - 1998. - Vol. 38. - P. 272.
87. Taniyama Y., Morishita R., Hiraoka K. et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes // Circulation. - 2001. - Vol. 104. - P. 2344-23450.
88. Thurston G., Suri C., Smith K. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 // Science. - 1999. - Vol. 286. - P. 2511-2514.
89. Tomita N., Morishita R., Taniyama Y. et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1 // Circulation. - 2003. - Vol. 107. - P. 1411-1417.
90. Unger E. F., Banai S., Shou M. et al. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs // Cardiovasc. Res. - 1993. - Vol. 27. - P. 785-791.
91. Unger E. F., Shou M., Sheffield C. D. et al. Extracardiac to coronary anastomoses support regional left ventricular function in dogs // Amer. J. Physiol. - 1993. - Vol. 264. - P. H1567-15674.
92. Vincent K. A., Shyu K. G., Luo Y. et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-lalpha/VPl6 hybrid transcription factor // Circulation. - 2000. - Vol. 102. - P. 2255-226l.
93. Wojta J., Kaun C., Breuss J. M. et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk1in human endothelial cells // Lab. Invest. - 1999. - Vol. 79. - P. 427-438.
94. Yanagisawa-Miwa A., Uchida Y., Nakamura F. et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor // Science. - 1992. - Vol. 257. - P. 1401-1403
95. Yee A., Rosengart T. Angiogenesis and gene therapy for the treatment of coronary artery disease Ch. 16 // Advanced therapy in cardiac surgary / Eds K. L. Franco, E. D. Verrier, 2-nd ed. - London: B C Deaker Inc., 2003.
96. Zhang Y., Li J., Partovian C. et al. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo // Amer. J. Physiol. Heart Circ. Physiol. - 2003. - Vol. 284. - P. H2078-2082.